Biotechnology

Gan & Lee

Gan & Lee released FY2026 Q1 earnings on April 22 After-Market (BJT), actual revenue CNY 878.11 M (forecast CNY 1.136 B), actual EPS CNY 0.33 (forecast CNY 0.57)

Gan & Lee released FY2025 earnings on April 22 After-Market (BJT), actual revenue CNY 4.052 B (forecast CNY 4.15 B), actual EPS CNY 1.93 (forecast CNY 1.87)

Gan & Lee released FY2025 Q4 earnings on April 22 After-Market (BJT), actual revenue CNY 1.005 B (forecast CNY 1.103 B), actual EPS CNY 0.5502 (forecast CNY 0.45)

Gan & Lee to Release FY2026 Q1 Earnings on April 23 After-Market (BJT), Forecast Revenue CNY 1.136 B, EPS CNY 0.57

Gan & Lee to Release FY2025 Earnings on April 23 After-Market (BJT), Forecast Revenue CNY 4.15 B, EPS CNY 1.87

Ganli Pharmaceutical and Xtalpi Reach AI Peptide Innovative Drug R&D Cooperation

Gan & Lee released FY2025 9 Months Earnings on October 30 After-Market (BJT), actual revenue CNY 3.047 B, actual EPS CNY 1.3808

Gan & Lee released FY2025 Q3 earnings on October 30 After-Market (BJT), actual revenue CNY 980.24 M (forecast CNY 1.14 B), actual EPS CNY 0.3605 (forecast CNY 0.51)

Gan & Lee to Release FY2025 Q3 Earnings on October 31 After-Market (BJT), Forecast Revenue CNY 1.14 B, EPS CNY 0.51

Founder of Ganli Pharmaceutical Resigns as Chairman, Chen Wei Takes Over

Ganli Pharmaceutical Completes First Patient Administration of GZR102

Gan & Lee released FY2025 Q2 earnings on August 7 After-Market (BJT), actual revenue CNY 1.082 B (forecast CNY 1.112 B), actual EPS CNY 0.4902 (forecast CNY 0.52)

Gan & Lee released FY2025 Semi-Annual Earnings on August 7 After-Market (BJT), actual revenue CNY 2.067 B, actual EPS CNY 1.02

Gan & Lee to Release FY2025 Semi-Annual Earnings on August 8, 2025 (BJT)

Ganli Pharmaceutical's Shareholder Sells 690,800 Shares

Ganli Pharma Reports Significant Increase in Net Profit in H1 2025

Ganli Pharmaceutical Announces Novel Protein Degradation Patent Application

Ganli Pharmaceutical's Net Profit Expected to Grow Over 100% in H1 2025

Ganli Pharmaceutical Expected Net Profit Increase of 100.73% to 114.12% in First Half of 2025

Ganli Pharmaceutical Shareholders Plan to Reduce Shares

603087

Gan & Lee Pharmaceuticals has signed an exclusive license agreement with JW Pharmaceutical for the commercialization of bofanglutide injection in South Korea. JW Pharmaceutical will develop and commercialize the drug, receiving a $5 million upfront payment and potential milestone payments totaling $76.1 million. Bofanglutide, a bi-weekly GLP-1 receptor agonist, is in Phase III trials for obesity, type 2 diabetes, and sleep apnea. This partnership aims to leverage JW's expertise in the metabolic disease market, enhancing patient care in South Korea.

Pharmaceutical Technology

Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation

Gan & Lee Pharmaceuticals announced that its once-weekly GZR4 Injection met primary endpoints in two pivotal phase 3 trials, SUPER-1 and SUPER-2. The trials showed GZR4 significantly reduced HbA1c levels compared to daily insulin treatments, with favorable safety profiles. The SUPER-1 trial involved insulin-naïve patients, while SUPER-2 included those previously treated with basal insulin. Results will be presented at a scientific conference and submitted for publication. GZR4 offers a promising alternative for type 2 diabetes management, reducing injection frequency and improving patient adherence.

prnewswire

09:36 ETGan & Lee Pharmaceuticals' Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints in Two Pivotal Phase 3 Clinical Trials: SUPER-1 and SUPER-2

688062

As of October 9, more than 170 listed companies in the pharmaceutical and biotechnology industry have undergone institutional research, with innovative drug companies such as Mabwell and Gan & Lee receiving significant attention. Institutions are focusing on the R&D investment in innovative drug pipelines, R&D progress, and business development transactions. Institutions believe that the trend of "innovation + internationalization" will continue, maintaining a positive outlook on the main line of innovative drugs, and expect new investment opportunities around the 2025 European Society for Medical Oncology

36Kr

Mabwell

Innovative pharmaceutical companies receive intensive research from institutions

600867

China Galaxy Securities released a research report indicating that the diabetes drug market is vast, with GLP-1 class drugs experiencing explosive growth due to their dual advantages of lowering blood sugar and weight loss. It is expected that the global market size will exceed USD 50 billion in 2024, while the Chinese market was CNY 8.7 billion in 2023 and is expected to increase to CNY 23.3 billion by 2025. The industry is evolving towards long-acting, multi-target, and innovative dosage forms, with significant potential for domestic substitution. Innovation has become the core theme, and the prospects for leading enterprises are promising

Zhitong

THDB

China Galaxy Securities: The future domestic substitution space for diabetes is broad, and innovation is expected to achieve a curve overtaking

002873

600557

The A-share innovative drug sector saw a short-term surge, with Kanion Pharmaceutical hitting the daily limit, and Gan & Lee, NuoSiLanDe, Xintian Pharma, and others rising significantly. The CPO concept continues to squeeze shorts, with Zhongji Xuchuang rising over 4%, and its total market value surpassing 300 billion yuan for the first time; Cambridge Technology has achieved three consecutive limit-ups in five days, and Dekeli has risen over 10%

- On August 19, A-shares rose, with major indices increasing, driven by sectors like communication equipment and pharmaceuticals, while AI hardware stocks remained active.  
- Hong Kong stocks experienced fluctuations, with the Hang Seng Index declining slightly, although sectors like steel and non-ferrous metals gained.  
- The bond market continued its downward trend, and domestic commodity futures mostly fell, with significant drops in coking coal and other commodities.

Wallstreetcn

Xintian Pharma

Kanion Pharmaceutical

The three major A-share indices rose collectively, with a significant increase in the biopharmaceutical sector. CPO continues to squeeze shorts, while Hong Kong stocks fluctuated and fell, tech stocks retreated, and government bonds and commodities declined

300404

The concept of weight loss drugs is fluctuating upward, with BOJI CRO and Gan & Lee hitting the daily limit, while Aorite, Deyuan Pharmaceutical, and Menohua are also rising

BOJI CRO

The concept of weight loss drugs fluctuates upward, with BOJI CRO and others hitting the limit up

Gan & Lee announced that Xutohongda will reduce its holdings by 3.3995 million shares through centralized bidding from July 29, 2025, to August 14, 2025, accounting for 0.57% of the company's total share capital. Director Jiao Jiao will reduce her holdings by 67,500 shares from August 11, 2025, to August 14, 2025, accounting for 0.0112% of the total share capital. The reduction plans of both shareholders have been completed, with Xutohongda currently holding 32.0737 million shares, accounting for 5.34%; Jiao Jiao holds 202,500 shares, accounting for 0.0337%

Gan & Lee: Xutohongda 0.57% reduction completed

Gan & Lee Pharmaceuticals announced that its wholly-owned subsidiary has successfully completed the administration of the first subject in the Phase II clinical trial of GZR102 injection. GZR102 is a fixed-ratio combination weekly formulation of basal insulin/GLP-1RA, designed to provide an effective and safe combination therapy for patients with type 2 diabetes. The drug maximizes the synergistic effect of the two medications through an innovative formulation, and is expected to enhance glycemic control while reducing adverse reactions

Gan & Lee: The first subject has been dosed in the Phase II clinical trial of GZR102 injection

Gan & Lee(603087.SH)